MolDX: Clonoseq Assay for Assessment of Minimal Residual Disease (MRD) in Patients with Specific Lymphoid Malignancies

The MolDX: Clonoseq® Assay for Assessment of Minimal Residual Disease (MRD) in Patients with Specific Lymphoid Malignancies has been created and published for notice under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT) and 03602 (WY).
 

Medicare published a National Coverage Decision, 90.2 Next-Generation Sequencing for Patients with Advanced Cancer with an effective date of 03/16/2018. This coverage decision allows Medicare Administrative Contractors to cover a next-generation sequencing test for cancer diagnoses in beneficiaries with advanced cancer who are seeking additional treatment. Contractors may cover up to one test per beneficiary per cancer diagnosis.
 

Effective Date:  03/04/2019

Source: https://med.noridianmedicare.com/web/jfb/article-detail/-/view/10534/moldx-clonoseq-assay-for-assessment-of-minimal-residual-disease-mrd-in-patients-with-specific-lymphoid-malignancies